ライフサイエンスコーパス: vomit

1 ergy, respiratory infections, diarrhoea, and vomiting).

2 verse effects (unpleasant taste, nausea, and vomiting).

3 Nevertheless, he still occasionally vomited.

4 younger children with less diarrhea and more vomiting.

5 for treating chemotherapy-induced nausea and vomiting.

6 ausea, constipation, anorexia, diarrhea, and vomiting.

7 o an adverse event, oxygen desaturation, and vomiting.

8 low risk of chemotherapy-induced nausea and vomiting.

9 concerning features, such as weight loss or vomiting.

10 eduction in PTH) and self-reported nausea or vomiting.

11 s and specific symptoms of pain, nausea, and vomiting.

12 acial dysmorphisms, and periods of fever and vomiting.

13 by risk for chemotherapy-induced nausea and vomiting.

14 nted acutely with severe epigastric pain and vomiting.

15 ing, eye bulging, bradycardia, cyanosis, and vomiting.

16 ad nausea and 15 (17%) versus three (5%) had vomiting.

17 spitalization, and frequency of diarrhea and vomiting.

18 complaints of epigastric abdominal pain and vomiting.

19 , headache, nausea, diarrhea, dizziness, and vomiting.

20 rodysesthesia syndrome, nausea, fatigue, and vomiting.

21 cluded myelosuppression, fatigue, and nausea/vomiting.

22 lled NK1R) can reduce symptoms of nausea and vomiting.

23 this dosage decreased diarrhea but increased vomiting.

24 rely stop drug due to significant nausea and vomiting.

25 om Index) for nausea (1.8 vs 1.0; P = .005), vomiting (1.6 vs 0.5; P = .001), and overall symptoms (1

26 and promethazine after 24 hours (episodes of vomiting, 1 [IQR, 0-5] for metoclopramide vs 2 [IQR, 0-3

27 ausea (12.4% and 9.1% vs 5.1% and 7.3%), and vomiting (10.4% and 7.5% vs 7.1% and 3.1%).

28 tigue (18 [56%] of 32 vs two [40%] of five), vomiting (12 [38%] of 32 vs zero), and anaemia (eight [2

29 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotr

30 eutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).

31 by anemia 15% (95% CI 3-31%), and nausea or vomiting 14% (95% CI 4-27%).

32 The most common serious adverse events were vomiting (14 [4%] in the ramucirumab group vs 21 [7%] in

33 atigue (26 [53%]), diarrhoea (17 [35%]), and vomiting (15 [31%]).

34 Of the 209 cases, 155 (75%) vomited, 164 (79%) had diarrhea, and 158 (76%) were nurs

35 appetite (20 [27%]; one [1%] grade >=3), and vomiting (17 [23%]).

36 adverse events were cough (38 [63%] of 60), vomiting (17 [28%]), pyrexia (17 [28%]), and rhinorrhoea

37 pain, 24% had nonbloody loose stool, 18% had vomiting, 18% had weight loss, and 5% had intermittent b

38 [54% vs 23%; P < .001] and grade 3/4 nausea/vomiting [20% vs 11%; P = .03]), while rates of grade 3

39 nts in the methotrexate group had nausea and vomiting (21.7%) than in the placebo group (3.9%; P = .0

40 inal symptoms (nausea [47%], diarrhea [36%], vomiting [21%]).

41 erythrodysaesthesia syndrome (87 [18%]), and vomiting (24 [5%]).

42 taste." The most common adverse events were vomiting (24% of patients), cough (21%), and pyrexia (21

43 th fever and nonspecific symptoms, including vomiting (26/58 [45%]), abdominal pain (31/58 [53%]), an

44 ombocytopenia (34 [7%] of 463 patients), and vomiting (27 [6%] of 463 patients).

45 vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting (29 [45%] vs 12 [18%]), and diarrhoea (22 [34%]

46 upper gastrointestinal hemorrhage (3%), and vomiting (3%).

47 in 5 participants receiving NAC [nausea and vomiting (3), anaphylaxis (1), pain at drip site (1)].

48 Rash (84 reports), itching (46 reports), and vomiting (30 reports) were the 3 most frequently occurri

49 events in patients aged 6 to <12 years were vomiting (32%) and headache (29%), and those in patients

50 espectively; nausea: 50 [4%] vs 24 [2%]; and vomiting: 32 [3%] vs 17 [1%]).

51 xygen desaturation (353 patients [5.6%]) and vomiting (328 [5.2%]) were the most common of these adve

52 st commonly (>= 25%) fatigue (33.3%), nausea/vomiting (33.3%), and infusion-related reaction (26.7%).

53 ea (56 [10%] of 556 vs 64 [11%] of 585), and vomiting (39 [7%] of 556 vs 23 [4%] of 585).

54 nstipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), d

55 nausea (75%), fatigue (70%), anorexia (64%), vomiting (43%), weight loss (32%), and diarrhea (32%), w

56 nd those in patients aged 3 to <6 years were vomiting (46%) and diarrhea (39%).

57 thrombocytopenia (70%), diarrhea (70%), and vomiting (48%) were the most common adverse events.

58 gue (70%), nausea (70%), anorexia (66%), and vomiting (49%), which were generally grade 1 or 2.

59 sensitivity (48%) and the least variance in vomiting (5%).

60 6% [49 of 57]), ataxia (54% [29 of 54]), and vomiting (54% [29 of 54]) were common initial clinical m

61 ported whoop (41.9% vs. 31.3%), post-tussive vomiting (58.1% vs. 47.9%) and apnea (37.3% vs. 29.0%);

62 up and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anaemia (62 [35%]) in the chemo

63 de 1/2 fatigue (87.1%) and grade 1 nausea or vomiting (67.7%) during follow-up.

64 confidence interval [CI], 7.2%-8.2%), nausea/vomiting 7.8% (95% CI, 7.1%-8.5%), and abdominal pain 2.

65 30.7% [95% CI, 26.8%-34.7%]; P = .01) and no vomiting (87.1% [95% CI, 83.8%-90.0%) vs 78.0% [95% CI,

66 1.6% [95% CI, 37.4%-45.3%]; P < .001) and no vomiting (91.8% [95% CI, 89.0%-94.0%] vs 82.2% [95% CI,

67 Common adverse events included nausea/vomiting (97%) and lack of appetite (54%).

68 associated with reduced odds of posttussive vomiting, a marker of more clinically significant illnes

69 ts or who experience breakthrough nausea and vomiting; a recommendation to administer dexamethasone o

70 ribed for a multitude of symptoms, including vomiting, abdominal pain and diarrhea.

71 25-year-old female presented with diarrhoea, vomiting, abdominal pain, and bloating.

72 alization included fever duration, diarrhea, vomiting, abdominal pain, and leukocytopenia.

73 percentage reporting bloody diarrhea, fever, vomiting, abdominal pain; percentage hospitalized; durat

74 For radiation-induced nausea and vomiting, adjustments were made to anatomic regions, ris

75 atic grade 2 or greater fatigue, nausea, and vomiting adverse events (AEs).

76 Importance: Nausea and vomiting affects approximately 85% of pregnant women.

77 In each treatment group, the risk of vomiting after administration of any dose of the study a

78 Vomiting after artemether-lumefantrine plus amodiaquine

79 children treated with ondansetron continued vomiting after the administration of the therapy vs 93%

80 The presence of nausea or vomiting after the onset of oral refeeding was not diffe

81 findings (>60 years, intoxication, headache, vomiting, amnesia, seizure, or trauma above the clavicle

82 staff) who vomited and infected considerably more secondary cases c

83 prokinetic effects and significantly reduced vomiting and also improved other symptoms of diabetic ga

84 Vomiting and bloody stool were frequently observed in bo

85 Vomiting and cough were prevalent symptoms in the first

86 t requiring surgery [grade 3]; recurrence of vomiting and dehydration [grade 3]; diarrhoea and fever

87 s each year as a result of severe diarrhoea, vomiting and dehydration due to the actions of cholera t

88 times since each patient's last episodes of vomiting and diarrhea were recorded.

89 The final patient developed vomiting and diarrhea, started palliative care, and died

90 l pain and high grade fever, associated with vomiting and frequent loose stools.

91 ea and G4 thrombocytopenia at 350 mg; and G3 vomiting and G3 diarrhea at 500 mg.

92 He was vomiting and in distress, and he had a history of thalas

93 to most tetracyclines, transient nausea and vomiting and low-magnitude increases in liver aminotrans

94 to compare complete response (CR) rates (no vomiting and no rescue medication) between the groups in

95 ients in whom there is absence of nausea and vomiting and no signs of severe ileus or gastrointestina

96 olonoscopic polypectomy with rigors, nausea, vomiting and right upper quadrant pain.

97 with evidence of dehydration associated with vomiting and severe diarrhea.

98 s ribavirin due to serious adverse events of vomiting and tachycardia.

99 ECS is involved in the control of nausea and vomiting and visceral sensation.

100 ildren (age, <18 years) with >=3 episodes of vomiting and/or diarrhea in a 24-h period and symptoms f

101 on-GII.4 viruses in children presenting with vomiting and/or diarrhea.

102 re, ranging from 0 (daily vomiting) to 4 (no vomiting), and the quality of life, assessed by the Gast

103 al (GI) symptoms, including diarrhea, nausea/vomiting, and abdominal pain, as well as liver enzyme ab

104 e pooled the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function

105 reaction including erythema, abdominal pain, vomiting, and anaphylactic shock.

106 than men, functional chest pain, dyspepsia, vomiting, and anorectal pain do not appear to vary by ge

107 o group were arthralgia, diarrhea, pruritus, vomiting, and chest pain.

108 , drowsiness, psychomotor impairment, nausea/vomiting, and constipation.

109 Mild nausea, vomiting, and diarrhea were the only side effects of let

110 4%, and 3% of patients experiencing nausea, vomiting, and diarrhea, respectively.

111 equent adverse events were low-grade nausea, vomiting, and diarrhea.

112 mptoms at diagnosis, combinations of nausea, vomiting, and diarrhea.

113 d anemia, thrombocytopenia, fatigue, nausea, vomiting, and diarrhea.

114 ant EVD case definitions (focusing on fever, vomiting, and diarrhoea).

115 nificantly associated with death were fever, vomiting, and diarrhoea.

116 Patients reported mild nausea and vomiting, and endoscopy revealed only minor self-limitin

117 ced cancer: pain, breathlessness, nausea and vomiting, and fatigue.

118 e world during childhood and cause diarrhea, vomiting, and fever.

119 e world during childhood and cause diarrhea, vomiting, and fever.

120 ominal pain, constipation, diarrhea, nausea, vomiting, and flatulence.

121 0(th) %ile of normal, 85.75 minutes), recent vomiting, and gastroparesis cardinal symptom index-daily

122 e the early signs of cerebral edema (nausea, vomiting, and headache) and intervene with IV 3% sodium

123 enia (n=4), diarrhoea (n=2), melena, stroke, vomiting, and intestinal infarction; all but one patient

124 tries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent ou

125 ropenia, oesophagitis, diarrhoea, nausea and vomiting, and mucositis were significantly worse in pati

126 unwellness marked by abdominal pain, nausea, vomiting, and nutritional failure or with associated com

127 ique on postoperative opioid use, nausea and vomiting, and pain scores.

128 iated with savolitinib were nausea, fatigue, vomiting, and peripheral edema.

129 d nonserious adverse events (i.e., diarrhea, vomiting, and rash) were less common in the azithromycin

130 nce and longitudinal prevalence of diarrhea, vomiting, and rash/sores.

131 female, professional diver, reported nausea, vomiting, and systemic hives 20 to 30 minutes after inge

132 mon clinical features include fever, nausea, vomiting, and tinnitus.

133 re (aspiration during intubation, nausea and vomiting, and venous injury or compromise).

134 al with acute abdominal pain, diarrhoea, and vomiting, and was admitted to the hospital because of de

135 epigastric pain, postprandial pain, nausea, vomiting, and weight loss.

136 ncurrent with fever of 38.0 degrees C and/or vomiting, and/or a constitutional/enteric symptom graded

137 d with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal live

138 d adverse events (grade 1 or 2) were nausea, vomiting, anorexia, and fatigue, which were well managed

139 -positive cases were younger, more likely to vomit (aOR, 2.6), to cough >/=14 days (aOR, 6.3), to hav

140 hat individuals, particularly residents, who vomit are more infectious and tend to drive norovirus tr

141 In Rome IV functional nausea and functional vomiting are now described.

142 analyses revealed perceived drunkenness and vomiting as the strongest predictors for hangover intens

143 educed the half-time of gastric emptying and vomiting, as well as nausea, abdominal pain, bloating, a

144 oup had CPAP-related adverse events, such as vomiting, aspiration, and nasal, skin, or eye trauma.

145 ninferiority analysis) and the occurrence of vomiting (assessed in a superiority analysis) within 30

146 is (MS) patients and to alleviate nausea and vomiting associated with chemotherapy in cancer patients

147 onists, used in the management of nausea and vomiting associated with radiation and chemotherapies.

148 timulation (GES) for treatment of refractory vomiting, associated or not with gastroparesis.

149 He first developed oral mucosa symptoms and vomiting at 4 years and 10 months of age, and they gradu

150 Patients with nausea and vomiting at baseline (n = 101) had an even greater decre

151 emergency room with the complaint of bloody vomiting, at the 36th week of gestation with a live sing

152 Lower doses were also associated with less vomiting beyond 30 minutes after administration.

153 ed trial of patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like s

154 symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like s

155 Chemotherapy-induced nausea and vomiting (CINV) is a significant toxicity of chemotherap

156 the risk of chemotherapy-induced nausea and vomiting (CINV), these factors are rarely considered whe

157 , ranging from 0.10 for anorexia to 0.54 for vomiting (Cohen kappa statistic).

158 her levels of pain, gas/bloating, and nausea/vomiting compared to the Normal group.

159 eaningful improvements in nausea and reduced vomiting, compared with placebo, in patients with idiopa

160 d gastric emptying and significantly reduced vomiting, compared with placebo.

161 proportion of individuals who experienced no vomiting (complete CIV control) during the phase of inte

162 Nausea, vomiting, constipation, and headache were more common in

163 definitions of grade of severity for nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, f

164 severe hypercalcemia with failure to thrive, vomiting, dehydration, and nephrocalcinosis.

165 a major peanut allergen that induces rashes, vomiting, diarrhea, and anaphylactic shock.

166 lstat than with placebo were abdominal pain, vomiting, diarrhea, and back pain.

167 IGBs from the patient's body causes nausea, vomiting, discomfort, and even gastric mucous damage.

168 therapeutic target to manage the nausea and vomiting during cancer therapies and in the treatment of

169 Vomiting during therapy sessions, after taking the study

170 topenia, gastrointestinal events (diarrhoea, vomiting, dysgeusia, mucositis), fatigue, and hyponatrae

171 ed with a shorter time period since the last vomiting episode (odds ratio 8.1; P = .04 within 3 hours

172 o 8.1; P = .04 within 3 hours since the last vomiting episode).

173 rrent or prior optic neuritis or intractable vomiting episodes more frequently, had shorter time to m

174 =2 vomiting episodes without diarrhea or 1-2 vomiting episodes plus 1-2 loose/liquid stools within 24

175 anded case definition of AGE (by adding >/=2 vomiting episodes without diarrhea or 1-2 vomiting episo

176 ry recall of postingestive aversive effects (vomiting), evoked by repeatedly touching the food with c

177 ient experienced grade >= 2 TEAEs of nausea, vomiting, fatigue, and asthenia.

178 than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal res

179 (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]).

180 rated gastric emptying (P < .03) and reduced vomiting frequency (by approximately 60%) and severity v

181 ite score of these 4 subjective symptoms and vomiting frequency and severity.

182 daily e-diaries, in which patients recorded vomiting frequency and symptom scores (nausea, abdominal

183 nts given relamorelin had a 75% reduction in vomiting frequency compared with baseline, but this diff

184 Hospitalization rates and diarrhea and vomiting frequency were not significantly different betw

185 Endpoints were change from baseline in vomiting frequency, composite DG Symptom Severity score,

186 vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (

187 neratinib vs 23 [2%] grade 3 with placebo), vomiting (grade 3: 47 [3%] vs five [<1%]), and nausea (g

188 n = 1), pain (group A, n = 2) and nausea or vomiting (group A, n = 1).

189 e predominated by nausea (>90% of cases) and vomiting (>80% of cases).

190 ever, lack of appetite related to nausea and vomiting, headache and significant malaise.

191 .89; 95% confidence interval [CI], .82-.97), vomiting (HR, 0.86; 95% CI, .75-.98), and fever (HR, 0.9

192 sis) with chronic (>12 months) of refractory vomiting (idiopathic, associated with a type 1 or 2 diab

193 esented with >=3 episodes of diarrhea and/or vomiting in a 24-hour period.

194 anzapine significantly improved CR rates for vomiting in children receiving the first cycle of HEC.

195 rse events were gastrointestinal (nausea and vomiting in four participants during pregnancy and three

196 e outbreaks that causes diarrhoea, fever and vomiting in humans.

197 e prevention of acute and delayed nausea and vomiting in patients receiving chemotherapy.

198 olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemoth

199 that GES reduced the frequency of refractory vomiting in patients with and without diabetes, although

200 d to prevent chemotherapy-induced nausea and vomiting in patients with cancer.

201 n and a 30% reduction in odds of posttussive vomiting in persons aged 19 months-64 years.

202 findings suggest an effective treatment for vomiting in positive FPIES OFCs and allow for more confi

203 dence on effective treatments for nausea and vomiting in pregnancy and hyperemesis gravidarum.

204 y end points were control of both nausea and vomiting in the acute posttreatment period (first 24 hou

205 Inclusion of vomiting in the case definition resulted in a 20% improv

206 , respectively), and incidence of nausea and vomiting in the PACU (4 of 19 [21.1%] and 6 of 24 [25%],

207 and 6 of 23 [26.1%] for incidence of nausea/vomiting in the PACU).

208 or less, parent-reported moderate or severe vomiting in the previous 24 h, parent-reported severe fe

209 transmission, it is to a lesser degree than vomiting in these settings.

210 participants), abdominal pain (in six), and vomiting (in five).

211 luded cough (in 19 [56%] of 34 patients) and vomiting (in ten [29%]).

212 Cases who vomited infected 2.12 (95% CI: 1.68, 2.68) times the num

213 The results suggest that recent vomiting is the major source of airborne norovirus and i

214 gain resulting from compensatory behaviors (vomiting, laxative use, fasting, overexercise) was signi

215 ormal" in afatinib, but not in "nausea" and "vomiting" listed on drug labels.

216 he multivariate logistic model, a history of vomiting, lower platelet count, elevated aspartate amino

217 reness with recall, postoperative nausea and vomiting, medical complications, and death.

218 of the legs or feet, abdominal pain, nausea, vomiting, melena, or hematochezia.

219 erature, age, recession, wheeze, asthma, and vomiting (mnemonic STARWAVe; AUROC 0.81, 0.76-0.85) dist

220 th 42.5% (17/40) coughing until the point of vomiting most days.

221 s generally include fever, headache, nausea, vomiting, muscle pain, lack of appetite, and rash.

222 ng hyperglycemia (n = 6), nausea (n = 7) and vomiting (n = 7).

223 most common symptoms were dehydration (n=2), vomiting (n=2), and proteinuria (n=2).

224 ), cough (n=32), nasopharyngitis (n=25), and vomiting (n=25).

225 events (nausea [n = 67], diarrhea [n = 84], vomiting [n = 20], and rash [n = 20]).

226 events (nausea [n = 89], diarrhea [n = 52], vomiting [n = 28], and rash [n = 31]) and patients in th

227 sh [n=1] in cohort 4, and grade 2 nausea and vomiting [n=1] and grade 4 immune-mediated hepatitis [n=

228 rse events across all groups were diarrhoea, vomiting, nasopharyngitis, falls, headache, insomnia, an

229 Vomiting, nausea, and headache were the only treatment-e

230 ntly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral neuropathy, wh

231 this condition is that the symptoms such as vomiting, nausea, loss of appetite and abdominal growth

232 Nausea or vomiting occurred more frequently in the sertraline vs p

233 henia, poor appetite, dizziness, nausea, and vomiting occurred significantly more frequently in the m

234 Nausea and vomiting of pregnancy (NVP) is a common condition that a

235 east moderate symptoms of chronic nausea and vomiting of presumed gastric origin for a minimum of 6 m

236 ss of consciousness (one), sepsis (one), and vomiting (one).

237 le for conditions as benign as headaches and vomiting or as severe as seizures, neurological damage,

238 otypes between children with >=3 episodes of vomiting or diarrhea within 24 h and <7 days of symptoms

239 an 18 years, with at least three episodes of vomiting or diarrhoea in the preceding 24 h and fewer th

240 Regarding harms, an increased burden of vomiting or nausea was observed in the oseltamivir group

241 Nausea/vomiting or sore throat/nose occurred in 17 of the 409 c

242 rpse, body fluids, or a case with diarrhoea, vomiting, or bleeding).

243 tool specimens in children with diarrhoea or vomiting, or both.

244 The most frequent toxic effects were nausea, vomiting, or diarrhea; an asymptomatic increase in the c

245 between treatment arms with postdose nausea, vomiting, or other adverse events.

246 hea, fever, myalgias/arthralgias, nausea, or vomiting (P < .05) at admission.

247 y to have myalgias/arthralgias (P< .001) and vomiting (P = .02).

248 eral nervous system, such as chronic nausea, vomiting, pain, and hypertension.

249 ale and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role functioning,

250 and control measures that focus on cases who vomit, particularly if those cases are residents.

251 ts were fatigue, nausea, diarrhea, anorexia, vomiting, peripheral sensory neuropathy, and keratitis/k

252 engue Identifier [ESDI]) included history of vomiting, platelet count, AST level.

253 perative infection, postoperative nausea and vomiting (PONV), or other complications.

254 ncluding migraines, postoperative nausea and vomiting (PONV), vertigo and morning sickness and observ

255 ltimodal analgesia, postoperative nausea and vomiting prophylaxis, early diet advancement, early ambu

256 kopenia; fever and at least two of nausea or vomiting, rash, aches and pains, positive tourniquet tes

257 Among patients with baseline vomiting, relamorelin had prokinetic effects and signifi

258 dications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pain, and

259 py with high chemotherapy-induced nausea and vomiting risk (32.4% [n = 106795]).

260 -certainty), and non-anaphylactic reactions (vomiting: RR 1.79 [95%CI 1.35-2.38], I(2)=0%, high-certa

261 Primary endpoints were vomiting score, ranging from 0 (daily vomiting) to 4 (no

262 Vomiting scores increased significantly when the device

263 cores over the 14-day study period, trend in vomiting scores was better in the ondansetron group (P =

264 During both phases of the crossover study, vomiting scores were higher in the group with the device

265 n; 10: the most pain imaginable), nausea and vomiting, sedation, minimal alveolar concentration of vo

266 ]), oral mucositis (three [2%] vs 14 [10%]), vomiting (seven [5%] vs seven [5%]), peripheral neuropat

267 patient questionnaires showed a reduction in vomiting (severity), diarrhea (both incidence and severi

268 p, included nausea, constipation, dizziness, vomiting, somnolence, fatigue, and sedation.

269 h populations and increased with addition of vomiting-specific codes.

270 hospital stay, readmission rate, nausea and vomiting symptoms, decrease in quality of life, psycholo

271 p), nausea (15 [4%] vs 17 [4%] patients) and vomiting (ten [2%] patients in each group); and nervous

272 The most common solicited event was vomiting (ten [8%] of 130 patients aged 24-59 months, 13

273 ea in children and were associated with less vomiting than the standard 20-mg dose.

274 ea (four [7%]), neutropenia (four [7%]), and vomiting (three [5%]).

275 (four [11%]), hypertension (four [11%]), and vomiting (three [8%]).

276 s were vomiting score, ranging from 0 (daily vomiting) to 4 (no vomiting), and the quality of life, a

277 In the 119 patients (58.3%) with baseline vomiting, twice-daily relamorelin significantly reduced

278 utoimmune toxicities (five [15%]), nausea or vomiting (two [6%]), and seizures (two [6%]).

279 cal neurologic deficits, chest pain, nausea, vomiting, unintentional weight loss, or recent trauma.

280 rs], retinopathy [urothelial carcinoma], and vomiting [urothelial carcinoma] in one patient each); no

281 patterns emerged for compensatory behaviors (vomiting, use of laxatives, and excessive exercise; 76.3

282 Postoperative nausea and vomiting was reported in 48 patients (7.8%) in the guide

283 Vomiting was significantly associated with GII.4 infecti

284 Grade 3 or 4 nausea and vomiting was the most common adverse event (ten particip

285 Vomiting was the most commonly reported mild adverse eve

286 "Bloody vomit" was noted.

287 based on the percentage of cases who stopped vomiting, was compared in cases who received parenteral

288 considered when symptoms such as nausea and vomiting, weight loss, melena, hematemesis and deep anem

289 econd trimester, symptoms such as nausea and vomiting, weight loss, melena, hematemesis and deep anem

290 Women reporting nausea/vomiting were less likely to be adherent in both the tam

291 Diarrhea, dizziness, and vomiting were more common in the difelikefalin group tha

292 Stomach pain, nausea, and vomiting were the most common adverse events reported (i

293 nt), and headache, dizziness, diarrhoea, and vomiting were the most frequent adverse events in patien

294 Mild to moderate nausea and vomiting were the most frequent treatment-emergent adver

295 , retinal vein occlusion, n=1 each; placebo: vomiting, white blood cell count increased, n=1 each).

296 nic trioxide because of grade 3 diarrhea and vomiting with concurrent grade 3 hypokalemia and hyponat

297 efficacy of GES in patients with refractory vomiting, with or without gastroparesis.

298 Vomiting within 30 minutes after administration occurred

299 th TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroart

300 Vomiting without diarrhea occurred among norovirus cases